Change and its clinical significance of T-lymphocyte subset in patients with hepatitis B virus-associated liver cancer
10.3969/j.issn.1673-4130.2019.03.020
- VernacularTitle:T细胞亚群在乙肝病毒相关性肝癌患者中的变化及其临床意义
- Author:
Yulin LIAO
1
;
Shuya HE
;
Xiaoyu SONG
Author Information
1. 四川省肿瘤医院检验科
- Keywords:
hepatitis B virus;
primary liver cancer;
cellular immunity;
T cell;
predictive analysis
- From:
International Journal of Laboratory Medicine
2019;40(3):338-341
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the expression of T cell subset in patients with hepatitis B virus-associated primary liver cancer (HBV-PLC) and its influence on the clinical outcome.Methods 136 cases with PLC were selected, and divided into HBV-PLC group (78 cases) and non-HBV-PLC group (58 cases) according to HBV infection.The percentage of CD4+T cells, CD8+T cells and Treg cells in serum was tested by flow cytometry.After 6 months of follow-up, HBV-PLC patients were divided into death group and survival group.Binary logistic regression analysis was performed to explore the factor and degree affecting clinical outcome of HBVPLC patients.Results As compared with non-HBV-PLC group, dysregualted T cell subset was observed in the HBV-PLC group, percentage of CD4+T cells and Treg cells in HBV-PLC patients was higher (P＜0.05), while CD8+T cell percentage was decreased (P＜0.05).The percentage of CD4+T cells and Treg cells was higher in death group than survival group (P＜0.05), but CD8+T cell percentage was lower than that of survival group (P＜0.05).T-lymphocyte subset (CD4+T cells and Treg cells) was a strong risk factor for adverse clinical outcome of HBV-PLC (OR values were 3.765 and 2.238, respectively, P＜0.05), but CD8+T cell was a protective factor (OR value was-3.537, P＜0.05).Conclusion Obvious dysfunction of T cellular immune function exists in HBV-PLC patients, and T cell subset may be a predictive factor for clinical outcome of HBV-PLC patients.
